Loading
Diabetes Mellitus Type 2 / Obesity & Overweight / Neoplasms · Observational Study
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a completed observational cohort study using electronic health records to examine associations between pre-diagnosis GLP-1 receptor agonist use and post-cancer mortality in adults with obesity and type 2 diabetes. No results are yet reported in this registry entry; the study compares GLP-1 RA with multiple other glucose-lowering therapies (SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care) across five primary outcome comparisons, all measuring all-cause mortality through 36 months post-cancer diagnosis.
Observational. Obesity & Overweight, Diabetes Mellitus Type 2, Neoplasms; age from 18 Years. Intervention: GLP-1 RA; Usual Care Without GLP-1 RA. Compared with: Other glucose-lowering therapies: SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care. n = 203,424. 1 site: Taiwan.
This is a registry record for a completed observational cohort study using electronic health records to examine associations between pre-diagnosis GLP-1 receptor agonist use and post-cancer mortality in adults with obesity and type 2 diabetes. No results are yet reported in this registry entry; the study compares GLP-1 RA with multiple other glucose-lowering therapies (SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care) across five primary outcome comparisons, all measuring all-cause mortality through 36 months post-cancer diagnosis.
No secondary outcomes, serious adverse events, or subgroup analyses are described in this registry entry.
The source did not state who this applies to in practice.
Registry record for an observational cohort study with recruitment completed but results not yet published; describes planned analysis of associations between pre-diagnosis GLP-1 RA use and post-cancer mortality in a large administrative database.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07513259). This is a study registration, not published results. Lead sponsor: Chung Shan Medical University. Recruitment status: COMPLETED. Study type: OBSERVATIONAL. Enrollment: 203424 participants (ACTUAL). Conditions: Obesity & Overweight, Diabetes Mellitus Type 2, Neoplasms. Primary outcome measures: All-cause Mortality (Comparison 1) , From obesity-associated cancer diagnosis through 36 months; All-cause Mortality (Comparison 2) , From obesity-associated cancer diagnosis through 36 months; All-cause Mortality (Comparison 3) , From obesity-associated cancer diagnosis through 36 months; All-cause Mortality (Comparison 4) , From obesity-associated cancer diagnosis through 36 months; All-cause Mortality (Comparison 5) , From obesity-associated cancer diagnosis through 36 months. Brief summary: This study will examine whether the type of diabetes treatment used before cancer diagnosis is associated with survival and serious complications after obesity-associated cancer in adults with obesity and type 2 diabetes. The study focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RA) and compares them with other commonly used glucose-lowering therapies, including SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care. Using de-identified electronic health record data from the TriNetX US Collaborative Network, the study will assess whether patients who used GLP-1 RA before cancer diagnosis have different risks of death, hospitalization, sepsis, and other major outcomes after cancer diagnosis. This is an observational study designed to evaluate associations in routine clinical care and not to prove a treatment effect.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.